|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 278,000 KRW | -0.71% |
|
-6.08% | -21.13% |
| 05-16 | Hanmi Pharm. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
Hanmi Pharm. Co., Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was KRW 228.61 million compared to KRW 2,570.12 million a year ago.
Net income was KRW 55,002.18 million compared to KRW 43,147.73 million a year ago. Basic earnings per share from continuing operations was KRW 4,337 compared to KRW 3,399 a year ago. Basic earnings per share was KRW 4,337 compared to KRW 3,399 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -21.13% | 2.55B | |
| +20.37% | 43.54B | |
| +18.30% | 21.78B | |
| +18.18% | 15.38B | |
| +25.55% | 15.12B | |
| +60.99% | 13.36B | |
| -0.05% | 6.79B | |
| -14.84% | 6.38B | |
| -8.87% | 5.73B | |
| +8.17% | 5.32B |
HANMI PHARM. CO., LTD. 
